All In Biotech

Drug Trial Radar · NCT06658964

Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects

A Single-center, Non-randomized, Open-label, Self-controlled Phase 1 Clinical Study to Evaluate Drug-drug Interactions of JMKX003142 Tablets in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

48

Planned (sponsor's estimate)

Start

Nov 5, 2024

Primary completion

Dec 10, 2024

Study completion Mar 21, 2025

Sponsor

Lead sponsor
JemincareIndustry
Sponsor type
Industry
Collaborators
Zhejiang Hangyu Pharmaceutical Co., Ltd.
First posted
Oct 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of JMKX003142 in healthy subjects.

Conditions

  • ADPKD (autosomal Dominant Polycystic Kidney Disease)

Interventions

  • Cohort 1: JMKX003142 and itraconazoleDrug

    JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning. Itraconazole:Dose: 200mg once;Day5-Day7 and Day9-Day11, QD

  • Cohort 2: JMKX003142 and rifampicinDrug

    JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning. Rifampicin:Dose: 600mg once;Day5-Day13 and Day15-Day17, QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of JMKX003142 in plasmaTime frame: approximately 5 days after JMKX003142 administered
  2. AUC of JMKX003142 in plasmaTime frame: approximately 5 days after JMKX003142 administered

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.